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fiducials were used. Optimal positioning of the fiducials 
did not improve the accuracy of the treatment when 
compared to the accuracy achieved with typical clinical 
fiducial positions or with three fiducials. Usage of only two 
fiducials in the target tracking resulted clinically 
unacceptable accuracy.  
   
PO-0865  Commissioning and clinical implementation of 
intra-fractional 4D-CBCT imaging for lung SBRT 
R. Sims1 
1ARO - Auckland Radiation Oncology, Radiotherapy 
Physics, Auckland, New Zealand 
 
Purpose or Objective  
Geometric verification of the tumour for free-breathing 
lung SBRT patients is challenging due to limitations of 
CBCT imaging at the treatment unit. This can be overcome 
by using novel acquisition and reconstruction tools to 
produce a 4D-CBCT dataset that can be acquired both 
before (inter-fraction) and during (intra-fraction) beam 
delivery. The commissioning and clinical experience of 
such a system for lung SBRT will be presented. 
Material and Methods  
An anthropomorphic phantom was used to investigate  
system efficacy for identifying changes in reconstructed 
motion with different acquisition settings for a variety of 
clinical situations. The sensitivity of the system to detect 
changes to programmed motion was investigated and 
compared to baseline 4DCT imaging with changes to image 
quality and kV absorbed dose being quantified using 
additional phantoms. The use of the system during MV 
treatment for VMAT deliveries was investigated and 
compared to baseline 4D-CBCT imaging with overall 
system performance being assessed in terms of image 
quality and image registration accuracy at the treatment 
console.  
Results  
For inter-fraction imaging, the system successfully 
identifies changes in amplitude motion to within ±2mm 
and is sensitive to image distortion/artefacts with 
different/irregular respiratory cycles and number of 
image projections. The absorbed dose for standard scan 
settings is 23.0 ± 1.6mGy with registration accuracy of 
±0.4mm and ±0.3degrees. When used intra-fraction there 
is a reduction in image quality owing to the dependence 
on VMAT delivery and MV scatter. This can be seen in 
Figure 1 as a function of VMAT arc length, with the quicker 
arcs resulting in poorer image quality (for a given BPM of 
the phantom). Measuring this in terms of contrast-to-noise 
ratio (between the tumour and surrounding lung tissue) 
demonstrates that as the arc length and breathing rate 
increases, the contrast-to-noise ratio approaches that of 
the inter-fraction 4D-CBCT (see Figure 2). The automatic 
4D matching algorithm was found to be influenced by 
image noise, causing a reduction in the measured 
amplitude of tumour motion, however despite this the 
accuracy of automatic registration was excellent varying 






Intra-fractional 4D-CBCT imaging has been implemented 
successfully and is now mandated for all lung SBRT 
patients at our clinic. The system has also been 
implemented for 3D spinal SBRT imaging although 
limitations of the MV scatter correction algorithm have 
resulted in our centre limiting the MU/Arc for VMAT 
delivery for these cases. Future studies will investigate 
different acquisition methods for existing conventionally-
fractionated treatments to improve the workflow and 
improve image quality. 
 
 
Poster: Physics track: Inter-fraction motion 
management (excl. adaptive radiotherapy)  
 
PO-0866  Visibility, image artifacts and proton dose 
perturbation of fiducial markers 
V.C. Hamming1, C.L. Brouwer1, M.J. Van Goethem1, R.I. 
Jolck2, C. Van Leijsen1, A.C.M. Van den Bergh1 
1UMCG University Medical Center Groningen, Radiation 
Oncology, Groningen, The Netherlands 
2NANOVI radiotherapy, DTU scion, Lyngby, Denmark 
 
Purpose or Objective  
Fiducial markers (FMs) are necessary for an accurate 
photon and proton radiation treatment for prostate-
cancer. However, conventional FMs may cause problems 
with dose calculations and perturbations in proton 
therapy. Therefore, specific proton-treatment FMs are 
available having smaller dimensions and different material 
compositions. The goal of this research was to survey the 
visibility, CT artifacts and proton dose perturbations of 
available FMs to choose the optimal FM for proton therapy. 
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Material and Methods  
The FMs used in this research were: BioXmark (NANOVI, 
300, 100, 50, 25 and 10µL (liquid)), BiomarC (Carbon 
Medical Technologies, Enhanced (1x5mm), Pro (0.9x5mm) 
and Standard (1x5mm)), Visicoil (IBA, 0.75x5mm, 
0.5x5mm), GoldAnchor (Naslund Medical, 0.28x10mm 
(open and folded)) and the fiducial gold marker (1x5mm, 
0.4x5mm). All these FMs were positioned in a gelatin 
phantom. The above mentioned FMs were rated for the 
marker visibility on CT (with and without image metal 
artifact reduction (IMAR)), MRI, 3D-CBCT (low (±36.6mAs) 
and high (±234.9mAs) dose) and MV imaging by means of 
the contrast to noise ratio (CNR). A CNR ≤ 1 was considered 
not visible whereas a CNR ≥ 5 was considered as visible. 
For the CT image the streak index (SI) was determined as 
well and was normalized to the fiducial gold marker 
(1x5mm). A normalized SI of 0 was considered to have no 
artifact, whereas a normalized SI of 1 was considered to 
have the largest artifact amongst the FM. 
Proton perturbation film measurements in a solid water 
phantom (SWP) were done at four different depths (5.4, 
5.6, 6.1, 7.1cm) for a selection of the FMs: fiducial gold 
marker 1x5mm, 0.4x5mm and the GoldAnchor 0.28x10mm 
folded. A circular (50mm diameter) proton beam of 190 
MeV was used to irradiate a dose of 7Gy in the Bragg peak. 
The Bragg peak was calculated to be at a depth of 7.1cm 
within the SWP. 
Needle sizes were also taken into account with regard to 
the necessity to temporarily stop anticoagulants.Results  
All FMs were visible on CT (Figure 1). Most of the FMs were 
visible on MRI except for the GoldAnchor (open), BiomarC 
(standard) and the visicoils. On 3D-CBCT all FMs were 
visible. In MV imaging for photon radiation treatment  the 
fiducial gold marker (1x5mm) and visicoil (0,75x5mm) 
were visible. The SI was maximal for the FM with gold and 
minimal for the BioXmark FM (Table 1).  
The fiducial gold marker (1x5mm) had the maximal proton 
dose perturbation measured which resulted in 10% 
underdosage at a depth of 7.1cm. For the other selected 
FMs no dose perturbation could be detected. 






The FM BioXmark 25 µL resulted in high visibility, low 
streak artifacts and smallest needle size.  
BioXmark is expected to have a smaller dose perturbation 
than was researched, because it has a lower atomic 
number and density than gold based FMs. In case larger 
volumes are needed a perturbation may become 
noticeable.  
   
PO-0867  Magnitude and robustness of motion 
mitigation in stereotactic body radiation therapy of the 
liver 
C. Heinz1, S. Gerum1, F. Kamp1, M. Reiner1, F. Roeder1 
1LMU Munich, Department of Radiation Oncology, Munich, 
Germany 
 
Purpose or Objective  
SBRT has been established as an effective treatment 
method of lesions located in the liver. However, 
respiratory induced motion has to be taken into account 
for tumor delineation and without proper motion 
mitigation techniques motion will result in undesirable 
increased treatment volumes. Abdominal compression has 
been described as an effective way to limit respiratory 
induced motion and thereby decrease treatment volumes. 
However, the whole workflow of motion estimation 
(4DCT), motion mitigation (abdominal compression), 
motion incorporation into planning (ITV delineation) and 
motion evaluation at each fraction (CBCT) depends 
strongly on the available equipment and is thereby 
specific to each department. Hence the achievable results 
in motion management are specific to a department and 
should be assessed. In this retrospective study the 
magnitude and robustness of abdominal compression was 
compared to a free breathing workflow using the specific 
equipment in our clinic. 
Material and Methods  
A total of 26 patients (abdominal compression n=11; free 
breathing n=15) that were treated with SBRT of the liver 
during 2011-2016 were analysed. Prior to the initial 
imaging fiducial markers were implanted next to each 
treatment target. Each patient received a 4DCT (Toshiba 
Medical Systems Corporation, Tokyo, Japan) from which a 
mean intensity projection CT (Mean CT) was generated 
(iPlan, Brainlab AG, Munich, Germany). Pre-treatment 
imaging included a conventional 3D-CBCT (Elekta AB, 
Stockholm, Sweden). Abdominal compression was realised 
using the BodyFIX system (Elekta AB, Stockholm, Sweden). 
Overall 74 fiducial markers (abdominal compression n=28; 
free breathing n=46) were analysed with regard to 
respiratory induced motion in the mean intensity 
projection CT as well as in all available 3D-CBCTs using an 
in-house developed software tool. The software provided 
a semi-automatic marker segmentation of the blurred 
markers and a motion estimation of the segmented 
markers using a principal component analysis. The 
estimated motion from the initial imaging was compared 
to the motion estimated from the pre-treatment 
imaging  in all major axes and 3D distance in magnitude 
(mean value) and robustness (standard deviation). 
Results  
Under free breathing patient data showed a mean marker 
movement (3D) of 19.8 mm in the Mean CT and 18.7 mm 
in the CBCT. By using the abdominal compression tool the 
mean marker movement was reduced to 15.7 mm in the 
Mean CT and 13.2 mm in the CBCT. Also the standard 
deviation of the 3D marker movement was reduced from 
3.6 mm to 1.7 mm in the Mean CT data and from 3.8 mm 
to 2.7 mm in the CBCT data (see figure 1). 
